{"id":51700,"date":"2022-12-07T22:05:29","date_gmt":"2022-12-07T21:05:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/"},"modified":"2022-12-07T22:05:29","modified_gmt":"2022-12-07T21:05:29","slug":"cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/","title":{"rendered":"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes"},"content":{"rendered":"
\n

BRISBANE, Calif–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR<\/a>) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the \u201cnotes\u201d) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d). Cutera also intends to grant the initial purchasers of the notes an option to purchase up to an additional $20 million aggregate principal amount of the notes.\n<\/p>\n

\nThe notes will be general senior, unsecured obligations of Cutera and will accrue interest payable semiannually in arrears. The notes will be convertible into cash, shares of Cutera\u2019s common stock (\u201ccommon stock\u201d) or a combination of cash and shares of Cutera\u2019s common stock, at Cutera\u2019s election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering.\n<\/p>\n

\nCutera intends to use a portion of the net proceeds from the offering to pay the aggregate cost of the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, Cutera expects to use a portion of the net proceeds from the sale of such additional notes to enter into additional capped call transactions. Cutera intends to use the remainder of net proceeds from the offering for general corporate purposes, which may include placements of AviClear, working capital, capital expenditures, potential acquisitions and strategic transactions, potential repurchases of its common stock and potential repurchases or exchanges of its existing convertible senior notes.\n<\/p>\n

\nIn connection with the pricing of the notes, Cutera expects to enter into capped call transactions with one or more of the initial purchasers and\/or their respective affiliates and\/or other financial institutions (the \u201coption counterparties\u201d). The capped call transactions are expected generally to reduce potential dilution to Cutera\u2019s common stock upon any conversion of notes, with such reduction subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Cutera expects to enter into additional capped call transactions with the option counterparties.\n<\/p>\n

\nCutera expects that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates may enter into various derivative transactions with respect to Cutera\u2019s common stock and\/or purchase shares of Cutera\u2019s common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Cutera\u2019s common stock or the notes at that time.\n<\/p>\n

\nIn addition, Cutera expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Cutera\u2019s common stock and\/or purchasing or selling Cutera\u2019s common stock or other securities of Cutera in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so on each exercise date for the capped call transactions). This activity could also cause or prevent an increase or a decrease in the market price of Cutera\u2019s common stock or the notes, and to the extent the activity occurs during any observation period related to a conversion of notes, this could affect the value of the consideration that a noteholder will receive upon conversion of its notes.\n<\/p>\n

\nNeither the notes, nor any shares of Cutera\u2019s common stock potentially issuable upon conversion of the notes, have been, nor will be, registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.\n<\/p>\n

\nThis press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nGreg Barker
\n
VP, Corporate FP&A
\n
415-657-5500
\n
IR@cutera.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BRISBANE, Calif–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the \u201cnotes\u201d) in a private placement to persons reasonably believed to be … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51700","6":"format-standard","7":"category-industry"},"yoast_head":"\nCutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the \u201cnotes\u201d) in a private placement to persons reasonably believed to be ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-07T21:05:29+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes\",\"datePublished\":\"2022-12-07T21:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/\"},\"wordCount\":740,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/\",\"name\":\"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-12-07T21:05:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/","og_locale":"en_US","og_type":"article","og_title":"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes - Pharma Trend","og_description":"BRISBANE, Calif–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the \u201cnotes\u201d) in a private placement to persons reasonably believed to be ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-07T21:05:29+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes","datePublished":"2022-12-07T21:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/"},"wordCount":740,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/","url":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/","name":"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-12-07T21:05:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cutera-inc-announces-proposed-private-offering-of-100-million-of-convertible-senior-notes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cutera, Inc. Announces Proposed Private Offering of $100 Million of Convertible Senior Notes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51700"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51700\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}